MARKET

KDNY

KDNY

Chinook Therapeutics Inc
NASDAQ
22.48
-0.17
-0.75%
After Hours: 22.48 0 0.00% 16:01 12/01 EST
OPEN
22.63
PREV CLOSE
22.65
HIGH
22.64
LOW
22.06
VOLUME
518.15K
TURNOVER
0
52 WEEK HIGH
23.86
52 WEEK LOW
11.16
MARKET CAP
1.44B
P/E (TTM)
-12.2801
1D
5D
1M
3M
1Y
5Y
Chinook Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook managemen...
GlobeNewswire · 11/22 21:05
BRIEF-Chinook Therapeutics Inc Files Prospectus Supplement For Potential Offering Of Up To $150 Million Of Common Stock
Reuters · 11/10 22:26
Chinook Therapeutics GAAP EPS of -$0.83 misses by $0.20, revenue of $2.5M beats by $2.38M
Seekingalpha · 11/10 22:14
Chinook Therapeutics Q3 EPS $(0.83) Down From $(0.69) YoY
Benzinga · 11/10 21:25
BRIEF-Chinook Therapeutics Inc Reports Q3 EPS Of $0.83
Reuters · 11/10 21:03
Chinook Therapeutics Q3 Loss Widens, Revenue Rises
Chinook Therapeutics Q3 Loss Widens, Revenue Rises
MT Newswires · 11/10 16:25
Insider Sell: Chinook Therapeutics
Insider Sell: Chinook Therapeutics
MT Newswires · 11/09 17:02
Chinook Therapeutics Presents Updated Data From BION-1301 Phase 1/2 Trial In Patients With IgA Nephropathy And CHK-336 Preclinical Efficacy Data At The American Society Of Nephrology Kidney Week 2022
Benzinga · 11/04 14:05
More
About KDNY
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing medicines for kidney diseases. Its lead product candidate is atrasentan, which is a selective endothelin A receptor antagonist that is developed for the treatment of proteinuric glomerular diseases. The Company’s second product candidate, BION-1301, is an investigational humanized IgG4 monoclonal antibody that blocks APRIL, a soluble factor that is implicated in IgAN and other indications, from binding to its receptors. Its third clinical development candidate is CHK-336, a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which is developed for the treatment of primary hyperoxaluria (PH), as well as secondary hyperoxaluria and idiopathic kidney stone formation. It is conducting a Phase I/II clinical trial of BION-1301.

Webull offers kinds of Chinook Therapeutics Inc stock information, including NASDAQ:KDNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDNY stock methods without spending real money on the virtual paper trading platform.